drugset
drugset / Trial / NCT00857714

Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast

NCT00857714 ↗

Terminated 1 enrolled Indiana University GlaxoSmithKline · collab
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to establish the utility of lapatinib in the treatment of DCIS, particularly ER-negative DCIS.

Timeline

Start
2009-04
Primary completion
2010-08
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule 1500 mg —

Indications

ductal breast carcinoma in situ